Status:
COMPLETED
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
Lead Sponsor:
InQpharm Group
Conditions:
Weight Loss
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of t...
Detailed Description
Appetite regulation plays an important role in determining the food intake, which is a complex process influenced by biological, behavioral and environmental stimuli. Satiation (intrameal satiety) is ...
Eligibility Criteria
Inclusion
- Age 18 to 65 years
- 25≤BMI≤35
- Expressed desire for weight loss
- Accustomed to 3 main meals/day
- Generally in good health
- Consistent and stable body weight 3 months prior to study enrolment
- Consistent regular physical activity
- Commitment to avoid the use of other weight loss products during study
- Commitment to adhere to diet and lifestyle recommended for the study
Exclusion
- Known sensitivity to the ingredients of the device
- Presence of any active gastrointestinal disease
- Malabsorption disorders
- Pancreatitis
- Stenosis in the GI tract
- Bariatric surgery
- Any other reason deemed suitable for exclusion, per investigator's judgement
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT01905956
Start Date
July 1 2013
End Date
July 1 2014
Last Update
March 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Grube
Berlin, State of Berlin, Germany, 10709